A Multicenter, Open-Label Study to Investigate the Safety and Tolerability of Intravenous Lacosamide as Replacement for Oral Lacosamide in Children (≥ 4 to < 17 Years of Age) With Epilepsy
Phase of Trial: Phase II/III
Latest Information Update: 14 Apr 2018
At a glance
- Drugs Lacosamide (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors UCB
- 07 Jun 2017 Status changed from not yet recruiting to recruiting.
- 22 May 2017 Planned End Date changed from 30 Jun 2020 to 14 Aug 2020.
- 22 May 2017 Planned primary completion date changed from 30 Jun 2020 to 14 Aug 2020.